Targets › SLITRK6
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
Regulator of neurite outgrowth required for normal hearing and vision. (UniProt, Q9H5Y7)
Open in Phaseline: the race on SLITRK6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | ADCT-701 anti-SLITRK6 antibody-drug conjugate | SLITRK6 | Phase 1 | Neuroendocrine Carcinomas | Oct 2027 |
Neuroendocrine Carcinomas (1)
small molecule (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.